Sporozoite immunization: innovative translational science to support the fight against malaria

INTRODUCTION Malaria, a devastating febrile illness caused by protozoan parasites, sickened 247,000,000 people in 2021 and killed 619,000, mostly children and pregnant women in sub-Saharan Africa. A highly effective vaccine is urgently needed, especially for Plasmodium falciparum (Pf), the deadliest human malaria parasite. AREAS COVERED Sporozoites (SPZ), the parasite stage transmitted by Anopheles mosquitoes to humans, are the only vaccine immunogen achieving > 90% efficacy against Pf infection. This review describes > 30 clinical trials of PfSPZ vaccines in the U.S.A., Europe, Africa, and Asia, based on first-hand knowledge of the trials and PubMed searches of 'sporozoites,' 'malaria,' and 'vaccines.' EXPERT OPINION First generation (radiation-attenuated) PfSPZ vaccines are safe, well tolerated, 80-100% efficacious against homologous controlled human malaria infection (CHMI) and provide 18-19 months protection without boosting in Africa. Second generation chemo-attenuated PfSPZ are more potent, 100% efficacious against stringent heterologous (variant strain) CHMI, but require a co-administered drug, raising safety concerns. Third generation, late liver stage-arresting, replication competent (LARC), genetically-attenuated PfSPZ are expected to be both safe and highly efficacious. Overall, PfSPZ vaccines meet safety, tolerability, and efficacy requirements for protecting pregnant women and travelers, with licensure for these populations possible within five years. Protecting children and mass vaccination programs to block transmission and eliminate malaria are long-term objectives.

[1]  G. E. Potter,et al.  A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria , 2022, Science Translational Medicine.

[2]  S. Hoffman,et al.  In vitro production of infectious Plasmodium falciparum sporozoites , 2022, Nature.

[3]  A. Pain,et al.  Creation and preclinical evaluation of genetically attenuated malaria parasites arresting growth late in the liver , 2022, npj Vaccines.

[4]  J. Kublin,et al.  A genetically engineered Plasmodium falciparum parasite vaccine provides protection from controlled human malaria infection , 2022, Science Translational Medicine.

[5]  S. Hoffman,et al.  A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection , 2022, NPJ vaccines.

[6]  G. E. Potter,et al.  PfSPZ-CVac malaria vaccine demonstrates safety among malaria-experienced adults: A randomized, controlled phase 1 trial , 2022, EClinicalMedicine.

[7]  Joana C. Silva,et al.  Plasmodium falciparum 7G8 challenge provides conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa , 2022, Nature Communications.

[8]  S. Hoffman,et al.  Efficacy, T cell activation and antibody responses in accelerated Plasmodium falciparum sporozoite chemoprophylaxis vaccine regimens , 2022, NPJ vaccines.

[9]  S. Hoffman,et al.  Cryopreserved Sporozoites with and without the Glycolipid Adjuvant 7DW8-5 Protect in Prime-and-Trap Malaria Vaccination. , 2022, The American journal of tropical medicine and hygiene.

[10]  S. Hoffman,et al.  Multi-Dose Priming Regimens of PfSPZ Vaccine: Safety and Efficacy against Controlled Human Malaria Infection in Equatoguinean Adults , 2022, The American journal of tropical medicine and hygiene.

[11]  S. Hoffman,et al.  Cryopreservation of Anopheles stephensi embryos , 2022, Scientific reports.

[12]  I. M. Gandidi,et al.  Vaccine cold chain management and cold storage technology to address the challenges of vaccination programs , 2021, Energy Reports.

[13]  M. Tshimanga,et al.  Factors associated with a malaria outbreak at Tongogara refugee camp in Chipinge District, Zimbabwe, 2021: a case–control study , 2021, Malaria journal.

[14]  S. Kappe,et al.  Malaria parasite liver stages. , 2021, Journal of hepatology.

[15]  G. E. Potter,et al.  Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial , 2021, Nature Medicine.

[16]  P. Njuguna,et al.  Safety and PCR monitoring in 161 semi-immune Kenyan adults following controlled human malaria infection , 2021, JCI insight.

[17]  A. Vaughan,et al.  Plasmodium vivax Latent Liver Stage Infection and Relapse: Biological Insights and New Experimental Tools. , 2021, Annual review of microbiology.

[18]  S. Hoffman,et al.  Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity , 2021, Nature.

[19]  U. d’Alessandro,et al.  Efficacy, Safety and Tolerability of Pyronaridine-artesunate in Asymptomatic Malaria-infected Individuals: a Randomized Controlled Trial , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  S. Hoffman,et al.  Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial , 2021, Nature Communications.

[21]  S. Hoffman,et al.  PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection , 2021, PLoS pathogens.

[22]  Erika L. Flannery,et al.  Partial protection against P. vivax infection diminishes hypnozoite burden and blood-stage relapses. , 2021, Cell host & microbe.

[23]  E. James.  Disrupting vaccine logistics , 2021, International health.

[24]  B. Gamain,et al.  Progress and Insights Toward an Effective Placental Malaria Vaccine , 2021, Frontiers in Immunology.

[25]  P. Duffy.  Transmission-Blocking Vaccines: Harnessing Herd Immunity for Malaria Elimination , 2021, Expert review of vaccines.

[26]  S. Hoffman,et al.  Immunogenicity and Protective Efficacy of Radiation-Attenuated and Chemo-Attenuated PfSPZ Vaccines in Equatoguinean Adults , 2020, The American journal of tropical medicine and hygiene.

[27]  Andrea A. Berry,et al.  Multidose Priming and Delayed Boosting Improve PfSPZ Vaccine Efficacy against Heterologous P. falciparum Controlled Human Malaria Infection. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  K. Matuschewski,et al.  Low immunogenicity of malaria pre‐erythrocytic stages can be overcome by vaccination , 2020, bioRxiv.

[29]  B. Everts,et al.  Plasmodium sporozoites induce regulatory macrophages , 2020, PLoS pathogens.

[30]  D. Lauffenburger,et al.  Mapping functional humoral correlates of protection against malaria challenge following RTS,S/AS01 vaccination , 2020, Science Translational Medicine.

[31]  Linda A. Murray,et al.  A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults , 2020, The Journal of infectious diseases.

[32]  S. Hoffman,et al.  Caregiver and community perceptions and experiences participating in an infant malaria prevention trial of PfSPZ Vaccine administered by direct venous inoculation: a qualitative study in Siaya County, western Kenya , 2020, Malaria Journal.

[33]  A. Vaughan,et al.  A replication-competent late liver stage-attenuated human malaria parasite. , 2020, JCI insight.

[34]  L. Coffeng,et al.  An open-label phase 1/2a trial of a genetically modified rodent malaria parasite for immunization against Plasmodium falciparum malaria , 2020, Science Translational Medicine.

[35]  S. Hoffman,et al.  A double-blind, placebo-controlled phase 1/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1 , 2020, Science Translational Medicine.

[36]  S. Hoffman,et al.  Feasibility of direct venous inoculation of the radiation-attenuated Plasmodium falciparum whole sporozoite vaccine in children and infants in Siaya, western Kenya. , 2020, Vaccine.

[37]  F. Wamunyokoli,et al.  Diversity and Multiplicity of P. falciparum infections among asymptomatic school children in Mbita, Western Kenya , 2020, Scientific Reports.

[38]  C. Jackson,et al.  Avid binding by B cells to the Plasmodium circumsporozoite protein repeat suppresses responses to protective subdominant epitopes , 2020, bioRxiv.

[39]  M. Wadsworth,et al.  Prevention of tuberculosis in macaques after intravenous BCG immunization , 2020, Nature.

[40]  J. Harty,et al.  You Shall Not Pass: Memory CD8 T Cells in Liver-Stage Malaria. , 2019, Trends in parasitology.

[41]  R. Sauerwein,et al.  Activatory Receptor NKp30 Predicts NK Cell Activation During Controlled Human Malaria Infection , 2019, Front. Immunol..

[42]  S. Hoffman,et al.  Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ Vaccine in Tanzanian adults. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  J. Kublin,et al.  Chemoprophylaxis vaccination: Phase 1 study to explore stage-specific immunity to Plasmodium falciparum in U.S. adults. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  R. Sauerwein,et al.  Fast and fierce versus slow and smooth: Heterogeneity in immune responses to Plasmodium in the controlled human malaria infection model , 2019, Immunological reviews.

[45]  S. Hoffman,et al.  Controlled human malaria infection of healthy lifelong malaria-exposed adults to assess safety, immunogenicity and efficacy of the asexual blood stage malaria vaccine candidate GMZ2. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  G. E. Potter,et al.  Dose dependent infectivity of aseptic, purified, cryopreserved Plasmodium falciparum 7G8 sporozoites in malaria-naive adults. , 2019, The Journal of infectious diseases.

[47]  S. Hoffman,et al.  Serologic Markers of Previous Malaria Exposure and Functional Antibodies Inhibiting Parasite Growth Are Associated With Parasite Kinetics Following a Plasmodium falciparum Controlled Human Infection , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  James B. Munro,et al.  Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential , 2019, Genome Medicine.

[49]  S. Hoffman,et al.  Safety and Differential Antibody and T-Cell Responses to the Plasmodium falciparum Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants , 2019, The American journal of tropical medicine and hygiene.

[50]  R. Sauerwein,et al.  Can Patrolling Liver-Resident T Cells Control Human Malaria Parasite Development? , 2019, Trends in immunology.

[51]  M. Netea,et al.  Outcomes of controlled human malaria infection after BCG vaccination , 2019, Nature Communications.

[52]  M. Schmid,et al.  Transcriptome analysis of Plasmodium berghei during exo-erythrocytic development , 2019, Malaria Journal.

[53]  S. Hoffman,et al.  Malaria vaccine trials in pregnant women: An imperative without precedent. , 2019, Vaccine.

[54]  S. Kappe,et al.  Designer Parasites: Genetically Engineered Plasmodium as Vaccines To Prevent Malaria Infection , 2019, The Journal of Immunology.

[55]  P. Njuguna,et al.  Controlled Human Malaria Infection in Semi-Immune Kenyan Adults (CHMI-SIKA): a study protocol to investigate in vivo Plasmodium falciparum malaria parasite growth in the context of pre-existing immunity , 2018, Wellcome open research.

[56]  M. Mamani-Matsuda,et al.  Human Vγ9Vδ2 T Lymphocytes in the Immune Response to P. falciparum Infection , 2018, Front. Immunol..

[57]  S. Thiberge,et al.  Cytotoxic anti-circumsporozoite antibodies target malaria sporozoites in the host skin , 2018, Nature Microbiology.

[58]  Joana C. Silva,et al.  A Plasmodium berghei sporozoite-based vaccination platform against human malaria , 2018, npj Vaccines.

[59]  S. Murphy,et al.  Prime-and-Trap Malaria Vaccination To Generate Protective CD8+ Liver-Resident Memory T Cells , 2018, The Journal of Immunology.

[60]  S. Hoffman,et al.  Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults , 2018, The American journal of tropical medicine and hygiene.

[61]  S. Hoffman,et al.  Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope , 2018, Science.

[62]  R. Saya,et al.  Immunization with one Theileria parva strain results in similar level of CTL strain-specificity and protection compared to immunization with the three-component Muguga cocktail in MHC-matched animals , 2018, BMC Veterinary Research.

[63]  Erika L. Flannery,et al.  Immunization of Malaria-Preexposed Volunteers With PfSPZ Vaccine Elicits Long-Lived IgM Invasion-Inhibitory and Complement-Fixing Antibodies , 2018, The Journal of infectious diseases.

[64]  J. Kublin,et al.  A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic Plasmodium falciparum Infection During Controlled Human Malarial Infection by Mosquito Bites and Direct Venous Inoculation , 2018, The Journal of infectious diseases.

[65]  S. Hoffman,et al.  A public antibody lineage that potently inhibits malaria infection by dual binding to the circumsporozoite protein , 2018, Nature Medicine.

[66]  S. Hoffman,et al.  Impact of Sickle Cell Trait and Naturally Acquired Immunity on Uncomplicated Malaria after Controlled Human Malaria Infection in Adults in Gabon , 2017, The American journal of tropical medicine and hygiene.

[67]  T. Horii,et al.  Immune evasion of Plasmodium falciparum by RIFIN via inhibitory receptors , 2017, Nature.

[68]  S. Hoffman,et al.  Advancing Global Health through Development and Clinical Trials Partnerships: A Randomized, Placebo-Controlled, Double-Blind Assessment of Safety, Tolerability, and Immunogenicity of PfSPZ Vaccine for Malaria in Healthy Equatoguinean Men , 2017, The American journal of tropical medicine and hygiene.

[69]  S. Hoffman,et al.  γδ T Cells Are Required for the Induction of Sterile Immunity during Irradiated Sporozoite Vaccinations , 2017, The Journal of Immunology.

[70]  M. Huynen,et al.  Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial , 2017, BMC Medicine.

[71]  C. Janse,et al.  Protective immunity differs between routes of administration of attenuated malaria parasites independent of parasite liver load , 2017, Scientific Reports.

[72]  A. Vaughan,et al.  Genetically attenuated malaria parasites as vaccines , 2017, Expert review of vaccines.

[73]  A. Vaughan,et al.  Malaria Parasite Liver Infection and Exoerythrocytic Biology. , 2017, Cold Spring Harbor perspectives in medicine.

[74]  K. Matuschewski,et al.  Engineering of Genetically Arrested Parasites (GAPs) For a Precision Malaria Vaccine , 2017, Front. Cell. Infect. Microbiol..

[75]  C. Janse,et al.  The use of transgenic parasites in malaria vaccine research , 2017, Expert review of vaccines.

[76]  D. Pratt,et al.  Role of controlled human malaria infection (CHMI) in malaria vaccine development: A U.S. food & drug administration (FDA) perspective. , 2017, Vaccine.

[77]  R. Germain,et al.  Prime and target immunization protects against liver-stage malaria in mice , 2018, Science Translational Medicine.

[78]  F. Frischknecht,et al.  Plasmodium Sporozoite Biology. , 2017, Cold Spring Harbor perspectives in medicine.

[79]  Sumana Chakravarty,et al.  Sterile protection against human malaria by chemoattenuated PfSPZ vaccine , 2017, Nature.

[80]  Sumana Chakravarty,et al.  Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. , 2017, JCI insight.

[81]  J. Kublin,et al.  Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects , 2017, Science Translational Medicine.

[82]  Scott N. Mueller,et al.  Liver-Resident Memory CD8+ T Cells Form a Front-Line Defense against Malaria Liver-Stage Infection. , 2016, Immunity.

[83]  T. Richie,et al.  Protective Efficacy of Plasmodium vivax Radiation-Attenuated Sporozoites in Colombian Volunteers: A Randomized Controlled Trial , 2016, PLoS neglected tropical diseases.

[84]  Paige E. Waterman,et al.  Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study. , 2016, The Journal of infectious diseases.

[85]  S. Hoffman,et al.  Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity , 2016, Malaria Journal.

[86]  Mario Roederer,et al.  Protection against malaria at 1 year and immune correlates following PfSPZ vaccination , 2016, Nature Medicine.

[87]  S. Hoffman,et al.  Safety, Immunogenicity, and Protective Efficacy of Intradermal Immunization with Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites in Volunteers under Chloroquine Prophylaxis: A Randomized Controlled Trial , 2016, The American journal of tropical medicine and hygiene.

[88]  A. McMichael,et al.  Evolution of the immune system in humans from infancy to old age , 2015, Proceedings of the Royal Society B: Biological Sciences.

[89]  S. Hoffman,et al.  Optimizing Intradermal Administration of Cryopreserved Plasmodium falciparum Sporozoites in Controlled Human Malaria Infection , 2015, The American journal of tropical medicine and hygiene.

[90]  M. Fried,et al.  Designing a VAR2CSA-based vaccine to prevent placental malaria✩ , 2015, Vaccine.

[91]  A. Barry,et al.  Designing malaria vaccines to circumvent antigen variability , 2015, Vaccine.

[92]  Q. Bassat,et al.  Strategies for Understanding and Reducing the Plasmodium vivax and Plasmodium ovale Hypnozoite Reservoir in Papua New Guinean Children: A Randomised Placebo-Controlled Trial and Mathematical Model , 2015, PLoS medicine.

[93]  S. Hoffman,et al.  Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine Development , 2015, PloS one.

[94]  S. Hoffman,et al.  Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity rates , 2015, Malaria Journal.

[95]  G. van Gemert,et al.  Heterologous Protection against Malaria after Immunization with Plasmodium falciparum Sporozoites , 2015, PloS one.

[96]  A. Vaughan,et al.  Mechanisms of Stage-Transcending Protection Following Immunization of Mice with Late Liver Stage-Arresting Genetically Attenuated Malaria Parasites , 2015, PLoS pathogens.

[97]  Charles C. Kim,et al.  FCRL5 Delineates Functionally Impaired Memory B Cells Associated with Plasmodium falciparum Exposure , 2015, PLoS pathogens.

[98]  S. Hoffman,et al.  Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres , 2015, Malaria Journal.

[99]  S. Hoffman,et al.  Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies , 2015, Malaria Journal.

[100]  G. van Gemert,et al.  Sporozoite Immunization of Human Volunteers under Mefloquine Prophylaxis Is Safe, Immunogenic and Protective: A Double-Blind Randomized Controlled Clinical Trial , 2014, PloS one.

[101]  S. Hoffman,et al.  Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection , 2014, Front. Microbiol..

[102]  S. Hoffman,et al.  Controlled Human Malaria Infection of Tanzanians by Intradermal Injection of Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites , 2014, The American journal of tropical medicine and hygiene.

[103]  S. Kappe,et al.  A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[104]  Samuel A. Assefa,et al.  A barcode of organellar genome polymorphisms identifies the geographic origin of Plasmodium falciparum strains , 2014, Nature Communications.

[105]  G. van Gemert,et al.  Cytotoxic Markers Associate With Protection Against Malaria in Human Volunteers Immunized With Plasmodium falciparum Sporozoites , 2014, The Journal of infectious diseases.

[106]  S. Hoffman,et al.  Two Plasmodium 6‐Cys family‐related proteins have distinct and critical roles in liver‐stage development , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[107]  R. Ahmed,et al.  PD-1 dependent exhaustion of CD8+ T cells drives chronic malaria. , 2013, Cell reports.

[108]  S. Kappe,et al.  First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. , 2013, Vaccine.

[109]  E. Gotuzzo,et al.  Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. , 2013, The American journal of tropical medicine and hygiene.

[110]  E. Hempelmann,et al.  Bad air, amulets and mosquitoes: 2,000 years of changing perspectives on malaria , 2013, Malaria Journal.

[111]  S. Hoffman,et al.  Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe , 2013, PloS one.

[112]  Bjoern Peters,et al.  Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP) , 2013, Malaria Journal.

[113]  R. Sauerwein,et al.  Liver or blood-stage arrest during malaria sporozoite immunization: the later the better? , 2013, Trends in parasitology.

[114]  S. Dalai,et al.  The Survival of Memory CD8 T Cells That Is Mediated by IL-15 Correlates with Sustained Protection Against Malaria , 2013, The Journal of Immunology.

[115]  A. Scott,et al.  Unique transcriptional profile of liver-resident memory CD8+ T cells induced by immunization with malaria sporozoites , 2013, Genes and Immunity.

[116]  M. Bevan,et al.  A T-cell response to a liver-stage Plasmodium antigen is not boosted by repeated sporozoite immunizations , 2013, Proceedings of the National Academy of Sciences.

[117]  D. Carucci,et al.  DNA Prime/Adenovirus Boost Malaria Vaccine Encoding P. falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity , 2013, PloS one.

[118]  Peter D. Crompton,et al.  Chronic Exposure to Plasmodium falciparum Is Associated with Phenotypic Evidence of B and T Cell Exhaustion , 2013, The Journal of Immunology.

[119]  S. Hoffman,et al.  Controlled Human Malaria Infections by Intradermal Injection of Cryopreserved Plasmodium falciparum Sporozoites , 2013, The American journal of tropical medicine and hygiene.

[120]  S. Hoffman,et al.  Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine. , 2013, Vaccine.

[121]  P. Brey,et al.  Visualizing Non Infectious and Infectious Anopheles gambiae Blood Feedings in Naive and Saliva-Immunized Mice , 2012, PloS one.

[122]  Q. Bassat,et al.  Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. , 2012, The Journal of infectious diseases.

[123]  S. Hoffman,et al.  Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA , 2012, Human vaccines & immunotherapeutics.

[124]  S. Dalai,et al.  Memory CD8 T Cells Specific for Plasmodia Liver-Stage Antigens Maintain Protracted Protection Against Malaria , 2012, Front. Immun..

[125]  M. Miyakoda,et al.  The species specificity of immunity generated by live whole organism immunisation with erythrocytic and pre-erythrocytic stages of rodent malaria parasites and implications for vaccine development. , 2012, International journal for parasitology.

[126]  K. Marsh,et al.  Naturally acquired immune responses against Plasmodium falciparum sporozoites and liver infection. , 2012, International journal for parasitology.

[127]  O. Doumbo,et al.  Next generation sequencing to detect variation in the Plasmodium falciparum circumsporozoite protein. , 2012, The American journal of tropical medicine and hygiene.

[128]  D. L. Guilbride,et al.  Malaria's deadly secret: a skin stage. , 2012, Trends in parasitology.

[129]  W. Weiss,et al.  Protective CD8+ T lymphocytes in Primates Immunized with Malaria Sporozoites , 2012, PloS one.

[130]  R. Sauerwein,et al.  Longevity and Composition of Cellular Immune Responses Following Experimental Plasmodium falciparum Malaria Infection in Humans , 2011, PLoS pathogens.

[131]  E. R. James,et al.  Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8+ T Cell Immunity , 2011, Science.

[132]  N. White.  Determinants of relapse periodicity in Plasmodium vivax malaria , 2011, Malaria Journal.

[133]  D. Carucci,et al.  Adenovirus 5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults , 2011, PloS one.

[134]  D. Carucci,et al.  Adenovirus-5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part B: Safety, Immunogenicity and Protective Efficacy of the CSP Component , 2011, PloS one.

[135]  A. Vaughan,et al.  Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. , 2011, Cell host & microbe.

[136]  J. Sacci,et al.  Identification of two new protective pre-erythrocytic malaria vaccine antigen candidates , 2011, Malaria Journal.

[137]  S. Hoffman,et al.  Immune responses and protection of Aotus monkeys immunized with irradiated Plasmodium vivax sporozoites. , 2011, The American journal of tropical medicine and hygiene.

[138]  F. Zavala,et al.  CD4+ T Cells Modulate Expansion and Survival but Not Functional Properties of Effector and Memory CD8+ T Cells Induced by Malaria Sporozoites , 2011, PloS one.

[139]  S. Thiberge,et al.  Development of the malaria parasite in the skin of the mammalian host , 2010, Proceedings of the National Academy of Sciences.

[140]  Bjoern Peters,et al.  Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein , 2010, Malaria Journal.

[141]  K. Matuschewski,et al.  Natural Immunization Against Malaria: Causal Prophylaxis with Antibiotics , 2010, Science Translational Medicine.

[142]  Sumana Chakravarty,et al.  Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria , 2010, Human vaccines.

[143]  S. Hoffman,et al.  The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. , 2009, The Journal of infectious diseases.

[144]  S. Kappe,et al.  Genetically Attenuated Parasite Vaccines Induce Contact-Dependent CD8+ T Cell Killing of Plasmodium yoelii Liver Stage-Infected Hepatocytes1 , 2009, The Journal of Immunology.

[145]  A. Aly,et al.  Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design , 2009, Proceedings of the National Academy of Sciences.

[146]  C. Rogier,et al.  Assessment of the relative success of sporozoite inoculations in individuals exposed to moderate seasonal transmission , 2009, Malaria Journal.

[147]  T. Richie,et al.  Immune evasion by malaria parasites: a challenge for vaccine development. , 2009, Current opinion in immunology.

[148]  R. Price,et al.  Parasite-Dependent Expansion of TNF Receptor II–Positive Regulatory T Cells with Enhanced Suppressive Activity in Adults with Severe Malaria , 2009, PLoS pathogens.

[149]  G. Di Giulio,et al.  Live immunization against East Coast fever--current status. , 2009, Trends in parasitology.

[150]  S. Hoffman,et al.  Gene Disruption of Plasmodium falciparum p52 Results in Attenuation of Malaria Liver Stage Development in Cultured Primary Human Hepatocytes , 2008, PloS one.

[151]  U. Frevert,et al.  Cellular effector mechanisms against Plasmodium liver stages , 2008, Cellular microbiology.

[152]  K. Matuschewski,et al.  A Sporozoite Asparagine-Rich Protein Controls Initiation of Plasmodium Liver Stage Development , 2008, PLoS pathogens.

[153]  I. Coppens,et al.  Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection , 2008, Molecular microbiology.

[154]  Xinxia Peng,et al.  A combined transcriptome and proteome survey of malaria parasite liver stages , 2008, Proceedings of the National Academy of Sciences.

[155]  M. Mota,et al.  Genetically attenuated P36p-deficient Plasmodium berghei sporozoites confer long-lasting and partial cross-species protection. , 2007, International journal for parasitology.

[156]  S. Hoffman,et al.  Cross-protection between attenuated Plasmodium berghei and P. yoelii sporozoites , 2007, Parasite immunology.

[157]  J. Sacci,et al.  CD8+ T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes , 2007, Nature Medicine.

[158]  A. Cowman,et al.  Plasmodium falciparum erythrocyte membrane protein-1 specifically suppresses early production of host interferon-gamma. , 2007, Cell host & microbe.

[159]  S. Kappe,et al.  Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells. , 2007, The Journal of infectious diseases.

[160]  S. Kappe,et al.  Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex Class I-dependent interferon-gamma-producing CD8+ T cells. , 2007, The Journal of infectious diseases.

[161]  Michelle M. Garrison,et al.  Freezing temperatures in the vaccine cold chain: a systematic literature review. , 2007, Vaccine.

[162]  J. Kublin,et al.  Dual Infection with HIV and Malaria Fuels the Spread of Both Diseases in Sub-Saharan Africa , 2006, Science.

[163]  T. J. Templeton,et al.  Variant antigen gene expression in malaria , 2006, Cellular microbiology.

[164]  M. Plebanski,et al.  Dimorphic Plasmodium falciparum merozoite surface protein‐1 epitopes turn off memory T cells and interfere with T cell priming , 2006, European journal of immunology.

[165]  S. Shorte,et al.  Quantitative imaging of Plasmodium transmission from mosquito to mammal , 2006, Nature Medicine.

[166]  Y. Chinzei,et al.  Two proteins with 6‐cys motifs are required for malarial parasites to commit to infection of the hepatocyte , 2005, Molecular microbiology.

[167]  R. Sinden,et al.  Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. , 2005, Immunity.

[168]  M. Mota,et al.  Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[169]  N. Steers,et al.  The immune status of Kupffer cells profoundly influences their responses to infectious Plasmodium berghei sporozoites , 2005, European journal of immunology.

[170]  S. Kappe,et al.  Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[171]  S. Kappe,et al.  Genetically modified Plasmodium parasites as a protective experimental malaria vaccine , 2005, Nature.

[172]  O. Skorokhod,et al.  Hemozoin (Malarial Pigment) Inhibits Differentiation and Maturation of Human Monocyte-Derived Dendritic Cells: A Peroxisome Proliferator-Activated Receptor-γ-Mediated Effect1 , 2004, The Journal of Immunology.

[173]  S. Hoffman,et al.  Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. , 2004, Vaccine.

[174]  L. Rénia,et al.  Protective T Cell Immunity against Malaria Liver Stage after Vaccination with Live Sporozoites under Chloroquine Treatment 1 , 2004, The Journal of Immunology.

[175]  S. Hoffman,et al.  Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine , 2003, Journal of Experimental Biology.

[176]  Jackie Williams,et al.  Protracted Protection to Plasmodium berghei Malaria Is Linked to Functionally and Phenotypically Heterogeneous Liver Memory CD8+ T Cells1 , 2003, The Journal of Immunology.

[177]  John Sidney,et al.  Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[178]  Ana Rodriguez,et al.  Malaria Blood Stage Suppression of Liver Stage Immunity by Dendritic Cells , 2003, The Journal of experimental medicine.

[179]  Jonathan E. Allen,et al.  Genome sequence of the human malaria parasite Plasmodium falciparum , 2002, Nature.

[180]  Patricia De la Vega,et al.  Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. , 2002, The Journal of infectious diseases.

[181]  A. Kelso,et al.  The Mechanism and Significance of Deletion of Parasite-specific CD4+ T Cells in Malaria Infection , 2002, The Journal of experimental medicine.

[182]  S. Hoffman,et al.  Incidence of symptomatic and asymptomatic Plasmodium falciparum infection following curative therapy in adult residents of northern Ghana. , 2001, The American journal of tropical medicine and hygiene.

[183]  S. Hoffman,et al.  The Complexity of Protective Immunity Against Liver-Stage Malaria1 2 , 2000, The Journal of Immunology.

[184]  P. De Baetselier,et al.  Hemozoin is a key factor in the induction of malaria‐associated immunosuppression , 1999, Parasite immunology.

[185]  S. Hoffman,et al.  IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. , 1999, Journal of immunology.

[186]  S. Hoffman,et al.  Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. , 1998, Science.

[187]  S. Hoffman,et al.  Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[188]  A. Holder,et al.  Characterization of human T- and B-cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: evidence for poor T-cell recognition of polypeptides with numerous disulfide bonds , 1997, Infection and immunity.

[189]  S. Hoffman,et al.  Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2 , 1995, The Journal of experimental medicine.

[190]  S. Hoffman,et al.  Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[191]  S. Hoffman,et al.  Complete protection against Plasmodium yoelii by adoptive transfer of a CD8+ cytotoxic T-cell clone recognizing sporozoite surface protein 2 , 1994, Infection and immunity.

[192]  B. Sina,et al.  Plasmodium falciparum sporozoite immunization protects against Plasmodium berghei sporozoite infection. , 1993, Experimental parasitology.

[193]  S. Hoffman,et al.  The role of CD4+ T cells in immunity to malaria sporozoites. , 1993, Journal of immunology.

[194]  S. Hoffman,et al.  A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei. , 1992, Journal of immunology.

[195]  L. Miller,et al.  Sporogonic development of a malaria parasite in vitro. , 1992, Science.

[196]  P. Romero,et al.  CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. , 1991, International immunology.

[197]  S. Hoffman,et al.  Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[198]  S. Hoffman,et al.  Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes , 1990, The Journal of experimental medicine.

[199]  V. Nussenzweig,et al.  Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria , 1989, Nature.

[200]  S. Hoffman,et al.  Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. , 1989, Science.

[201]  V. Nussenzweig,et al.  γ Interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites , 1987, Nature.

[202]  S. Hoffman,et al.  Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. , 1987, Science.

[203]  H. Webster,et al.  Antigen-specific immunosuppression in human malaria due to Plasmodium falciparum. , 1986, The Journal of infectious diseases.

[204]  W. Szmuness,et al.  Hepatitis B vaccine administered to chronic carriers of hepatitis b surface antigen. , 1982, Annals of internal medicine.

[205]  R. Beaudoin,et al.  Plasmodium berghei: immunization of mice against the ANKA strain using the unaltered sporozoite as an antigen. , 1977, Experimental parasitology.

[206]  D. Clyde,et al.  Plasmodium vivax: correlation of circumsporozoite precipitation (CSP) reaction with sporozoite-induced protective immunity in man. , 1977, Experimental parasitology.

[207]  D. Clyde,et al.  Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. , 1975, The American journal of tropical medicine and hygiene.

[208]  R. Miller,et al.  Specificity of protection of man immunized against sporozoite‐induced falciparum malaria , 1973, The American journal of the medical sciences.

[209]  J. Vanderberg,et al.  Immunization of man against sporozite-induced falciparum malaria , 1973, The American journal of the medical sciences.

[210]  J. Vanderberg,et al.  Sporozoite-induced immunity in mammalian malaria. A review. , 1972, The American journal of tropical medicine and hygiene.

[211]  W. Collins,et al.  Immunization of monkeys against Plasmodium cynomolgi by X-irradiated sporozoites. , 1972, Nature: New biology.

[212]  J. Vanderberg,et al.  Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei , 1967, Nature.

[213]  W. Richards.  Active Immunization of Chicks against Plasmodium gallinaceum by Inactivated Homologous Sporozoites and Erythrocytic Parasites , 1966, Nature.

[214]  I. McGregor,et al.  Antibody response to tetanus toxoid inoculation in malarious and non-malarious Gambian children , 1962 .

[215]  J. Freund,et al.  IMMUNIZATION OF RHESUS MONKEYS AGAINST MALARIAL INFECTION (P. KNOWLESI) WITH KILLED PARASITES AND ADJUVANTS. , 1945, Science.

[216]  J. Freund,et al.  IMMUNIZATION AGAINST MALARIA: VACCINATION OF DUCKS WITH KILLED PARASITES INCORPORATED WITH ADJUVANTS , 1945, Science.

[217]  P. F. Russell,et al.  THE IMMUNIZATION OF FOWLS AGAINST MOSQUITO-BORNE PLASMODIUM GALLINACEUM BY INJECTIONS OF SERUM AND OF INACTIVATED HOMOLOGOUS SPOROZOITES , 1942, The Journal of experimental medicine.

[218]  Alex B. Miller,et al.  A human monoclonal antibody prevents malaria infection and defines a new site of vulnerability on Plasmodium falciparum circumsporozoite protein , 2018 .

[219]  M. Good,et al.  CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[220]  T. Burkot,et al.  Infectivity to mosquitoes of Plasmodium falciparum clones grown in vitro from the same isolate. , 1984, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[221]  R. Nussenzweig,et al.  Comparative studies on the immunogenicity of infective and attenuated sporozoites of Plasmodium berghei. , 1982, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[222]  K. Sell,et al.  Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. , 1974, Transactions of the Royal Society of Tropical Medicine and Hygiene.